Overview

Intravitreal Dexamethasone Implant (Ozurdex) Versus Bevacizumab in Patients With Diabetic Macular Edema Undergoing Cataract Surgery

Status:
Withdrawn

Trial end date:
2021-01-31

Target enrollment:

Participant gender:

Summary

The purpose of this research is to compare the effectiveness of bevacizumab (Avastin) with another a dexamethasone implant (Ozurdex), with respect to anatomic and visual outcomes as well as injection frequency in subjects undergoing cataract surgery with a concurrent diagnosis of diabetic macular edema (DME).

Phase:

N/A

Details

Lead Sponsor:

Los Angeles Biomedical Research Institute
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Collaborators:

Allergan
Doheny Image Reading Center

Treatments:

BB 1101
Bevacizumab
Dexamethasone
Dexamethasone acetate